Molecular, Cellular, and Tissue Characterization Unit

分子、细胞和组织表征单元

• 批准号: 10461044
• 负责人: William E. Gillanders
• 金额: $ 98万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-30 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10461044
• 关键词: Adjuvant Therapy; Antibodies; Apoptosis; Atlases; Biopsy; Cell Proliferation; Cells; Clinical Data; Collection; Complement; Coupled; Cytometry; DNA; Data; Data Analyses; Data Set; Diagnosis; Diffusion; Disease; Disseminated Malignant Neoplasm; Elements; Evaluation; Excision; Future; Glioblastoma; Goals; Histology; Human; Image; Imaging technology; Immune; Immune Targeting; Immunofluorescence Immunologic; Immunotherapy; Individual; Link; Location; Magnetic Resonance Imaging; Malignant - descriptor; Malignant Neoplasms; Malignant neoplasm of brain; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of pancreas; Metadata; Metastatic to; Mission; Molecular; Nature; Neoadjuvant Therapy; Neoplasm Metastasis; Non-Malignant; Operative Surgical Procedures; Pancreatic Ductal Adenocarcinoma; Patient Recruitments; Patients; Phenotype; Primary Neoplasm; Procedures; Prognosis; Proteins; RNA; Recurrence; Research; Research Personnel; Resistance; Resistance development; Sampling; Signal Transduction; Site; Slide; Specimen; Stromal Cells; Structure; Technology; Time; Tissues; Training; Tumor-infiltrating immune cells; Universities; Washington; Work; aggressive breast cancer; base; cancer stem cell; cancer type; cellular imaging; design; in vivo; insight; molecular phenotype; multidimensional data; multiplexed imaging; neoplastic cell; new technology; novel; optical imaging; patient response; protein activation; protein metabolite; radiomics; response; single cell analysis; single-cell RNA sequencing; therapeutic development; therapy resistant; traditional therapy; transcriptome sequencing; treatment response; triple-negative invasive breast carcinoma; tumor; tumor microenvironment

Project Summary/Abstract: Biospecimen Unit The over-arching goal of the Biospecimen Unit for the Washington University Human Tumor Atlas Research Center (WU-HTARC) is to collect human tumor biospecimens for use by the Characterization and Data Analysis Units to construct the proposed tumor atlases. Our Biospecimen Unit will procure and bank longitudinal biopsies and excised tumors from 300-375 patients (selected from ~750 recruited patients) with a goal toward studying the transition from primary malignancy to recurrence and metastasis in conjunction with the development of therapeutic resistance in triple negative breast cancer (TNBC), glioblastoma (GBM), and pancreatic ductal adenocarcinoma (PDAC). Each of the three tumors chosen for this study poses unique challenges for both clinicians and researchers. From their often late onset of diagnosis, highly metastatic nature, challenges in achieving complete surgical resection, and primary and acquired resistance to treatment, each of these tumors represents an opportunity identified by the NCI Cancer Moonshot Initiative (CMI) to significantly advance our understanding of cancer and how to intervene on its initiation and progression. To support the overall mission of WU-HTARC, the Biospecimen Unit will perform the following: (1) identification of eligible patients at WU with TNBC, GBM, and PDAC; (2) rigorous and systemic collection of tumors, including longitudinal collection of all patients throughout their treatment course; (3) complete collection of associated clinical data and metadata; and (4) storage and processing of all samples with current and future experimental and analytical pipelines. The Biospecimen Unit will work closely with other Units within WU-HTARC to develop standard operating procedures and to make adjustments in line with the changing technologies.

项目概要/摘要：生物标本单元 华盛顿大学人类肿瘤图谱研究生物标本组的超额目标 中心（WU-HTARC）将采集人类肿瘤生物标本，供表征和数据分析使用 分析单元，以构建拟定的肿瘤图谱。我们的生物样本组将从 来自300-375名患者（选自约750名招募的患者）的纵向活检和切除的肿瘤， 目的是研究从原发性恶性肿瘤到复发和转移的转变， 三阴性乳腺癌（TNBC）、胶质母细胞瘤（GBM）和 胰腺导管腺癌（PDAC）。本研究选择的三种肿瘤中的每一种都具有独特的 对临床医生和研究人员的挑战。从他们往往迟发诊断，高度转移 性质，实现完全手术切除的挑战，以及对治疗的原发性和获得性抵抗， 这些肿瘤中的每一个都代表了NCI癌症登月计划（CMI）确定的机会， 大大提高了我们对癌症以及如何干预其发生和发展的认识。到 为了支持WU-HTARC的总体使命，生物标本股将执行以下任务：（1）识别 符合条件的WU TNBC、GBM和PDAC患者;（2）严格和系统性收集肿瘤，包括 在整个治疗过程中纵向收集所有患者;（3）完整收集相关的 临床数据和元数据;以及（4）存储和处理具有当前和未来实验的所有样品。 和分析管道。生物标本股将与WU-HTARC内的其他单位密切合作， 标准作业程序，并根据不断变化的技术作出调整。